Perinatal management of a preterm neonate affected by hyperprostaglandin E2 syndrome (HPS).
BACKGROUND
Neonates affected by hyperprostaglandin E(2) syndrome (HPS) present with severe polyuria. Both urinary losses as well as prostaglandin synthesis inhibitors may precipitate acute renal failure (ARF).


OBJECTIVE
Our goal was to maintain euvolaemia by replacement of urinary losses.


METHODS
Our patient was born prematurely with a family history typical of HPS. Urinary salt and water losses and PGE(2) excretion were determined in 2- to 4-h intervals. Salt and water were replaced accordingly.


RESULTS
Within the first 48 h, urinary losses and PGE(2) increased continuously to 50 ml/kg/h and 374 ng/h/1.73 m(2), respectively. Following exposure to 0.05-0.5 mg/kg/d indomethacin, urinary output decreased steadily to 10-15/ml/kg/h.


CONCLUSIONS
In euvolaemic preterm neonates with HPS and the need for excessive replacement of salt and water, inhibition of renal PGE(2) excretion with indomethacin effectively reduces polyuria and natriuresis without acutely compromising renal function.
Kömhoff
Martin
M
Department of Paediatrics, Philipps University Marburg, Marburg, Germany. koemhoff@med.uni-marburg.de
Tekesin
Ismail
I
Peters
Melanie
M
Leonhard
Andreas
A
Seyberth
Hannsjörg W
HW
D001477:Bartter Syndrome / Q000628:therapy*; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D007231:Infant, Newborn; D018743:Perinatal Care; D051437:Renal Insufficiency / Q000517:prevention & control
D016861:Cyclooxygenase Inhibitors; D007213:Indomethacin